What You Should Know:– Sanofi has agreed to acquire Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), for $25.00 per share in cash, representing an equity value of…
Source: hitconsultant.net – Read more
When “Goodbye” isn’t the end: Scattered LAPSUS$ Hunters hack on
“Goodbye isn’t the end. It’s the beginning of what happens next.” — Joshua Shaw Reading the news, I see some headlines suggesting that “Scattered LAPSUS$
